专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004085421A3 BIOREDUCTIVELY-ACTIVATED PRODRUGS 审中-公开
标题翻译：生物活性物质
公开(公告)号：WO2004085421A3
公开(公告)日：2005-03-24
申请号：PCT/GB2004001330
申请日：2004-03-26
申请人： ANGIOGENE PHARM LTD , GRAY LAB CANCER RES TRUST , DAVIS PETER DAVID , NAYLOR MATTHEW ALEXANDER , THOMSON PETER , EVERETT STEVEN ALBERT , STRATFORD MICHAEL RICHARD LACE , WARDMAN PETER
发明人： DAVIS PETER DAVID , NAYLOR MATTHEW ALEXANDER , THOMSON PETER , EVERETT STEVEN ALBERT , STRATFORD MICHAEL RICHARD LACE , WARDMAN PETER
IPC分类号： A61K31/445 , C07D233/54 , C07D233/91 , C07D333/42 , C07D409/04 , C07D473/38 , C07D519/00 , C07D333/36 , C07D417/04
CPC分类号： C07D409/04 , A61K31/445 , C07D233/91 , C07D333/42 , C07D473/38
摘要： The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: Ar is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3) wherein R1, and R2, which may be the same or different are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, COR3 or, together with the intervening carbon atom, form an optionally substituted heterocycloalkyl or carbocyclic ring ; L is -OC(O)- or -OP(O)(OR6)-; n is0or1;X is 0, S, NR7 or a single covalent bond; R3 is OR4 or NR4R5; R4, R5, R6 and R7 are each independently hydrogen or optionally substituted alkyl or, where Rr is NR4R5, R4 and R5 can be joined to form, together with the intervening nitrogen atom, a heterocycloalkyl ring; R8 is hydrogen, alkoxy or diatkylaminoalkyl; R9 is optionally substituted alkyl; R10 is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R11 and R12 are independently hydrogen, alkyl, alkoxy, thioatkoxy, amino, alkylamino, dialkylamino, morpholino, piperidino,piperazino or l-aziridinyl; A is an optionally substituted aryl or heteroaryl ring; and Dr is a moiety such that DrXH represents a cytotoxic or cytostatic compound.
摘要翻译：本发明涉及式（1）化合物或其药学上可接受的盐，其中：Ar是具有至少一个硝基或叠氮基的取代的芳基或杂芳基，或者是式（2）或（3）的基团）其中可以相同或不同的R 1和R 2独立地是任选取代的烷基，任选取代的烯基，任选取代的炔基，芳基，COR 3或与中间碳原子一起形成任选取代的杂环烷基或碳环; L是-OC（O） - 或-OP（O）（OR 6） - ; n为0或1; X为0，S，NR 7或单个共价键; R3是OR4或NR4R5; R 4，R 5，R 6和R 7各自独立地为氢或任选取代的烷基，或其中R r为NR 4 R 5，可以连接R 4和R 5与杂环氮原子一起形成杂环烷基环; R8是氢，烷氧基或二烷基氨基烷基; R9是任选取代的烷基; R 10是氢，烷基，烷氧基或二烷基氨基烷基; R 11和R 12独立地是氢，烷基，烷氧基，硫代烷氧基，氨基，烷基氨基，二烷基氨基，吗啉代，哌啶子基，哌嗪基或1-氮杂环丁烷基; A是任选取代的芳基或杂芳基环; Dr是一个部分，使得DrXH代表细胞毒性或细胞抑制性化合物。

2. 发明申请

WO2006067411A3 PROCESS FOR PREPARING A PHOSPHORYLATED COLCHINOL DERIVATIVE 审中-公开
标题翻译：制备磷酸氢化胆碱衍生物的方法
公开(公告)号：WO2006067411A3
公开(公告)日：2006-08-24
申请号：PCT/GB2005004933
申请日：2005-12-19
申请人： ANGIOGENE PHARM LTD , BROADY SIMON DANIEL , GOLDEN MICHAEL DAVID , LEONARD JOHN , MUIR JAMES CAMPBELL , BILLARD AULELIE , MURRAY KATIE
发明人： BROADY SIMON DANIEL , GOLDEN MICHAEL DAVID , LEONARD JOHN , MUIR JAMES CAMPBELL , BILLARD AULELIE , MURRAY KATIE
IPC分类号： C07F9/12
CPC分类号： C07F9/12
摘要： Process for preparing a phosphorylated colchinol derivative of formula (I): wherein each R, which may be the same or different, is selected from (1-6C)alkyl, benzyl and C(O)(1-6C)alkyl, or two RO groups together form a (1-4C)alkylenedioxy group; by hydrolysing a compound of formula (II) wherein X is halogeno and each R is as hereinbefore defined. Processes for crystallising compounds of formula (I) and for preparing compounds of formula (II) are also described.
摘要翻译：制备式（I）的磷酸化可待因醇衍生物的方法：其中每个R可以相同或不同，选自（1-6C）烷基，苄基和C（O）（1-6C）烷基或二 RO基团一起形成（1-4C）亚烷基二氧基; 通过水解其中X为卤素且每个R如上文所定义的式（II）化合物。还描述了用于结晶式（I）化合物和制备式（II）化合物的方法。

3. 发明申请

WO0100854A2 CHIMERIC PROTEINS MEDIATING TARGETED APOPTOSIS 审中-公开
标题翻译：嵌合蛋白介导靶向性凋亡
公开(公告)号：WO0100854A2
公开(公告)日：2001-01-04
申请号：PCT/GB0002449
申请日：2000-06-26
申请人： ANGIOGENE PHARM LTD , DAVIS PETER DAVID
发明人： DAVIS PETER DAVID
IPC分类号： A61K38/00 , C07K14/705 , C07K14/71 , C12N15/62 , A61K38/17 , C07K19/00
CPC分类号： C07K14/70585 , A61K38/00 , C07K14/70525 , C07K14/70578 , C07K14/71 , C07K2319/00
摘要： Chimeric cell-surface proteins are described which may be used in the selective induction of apoptosis in particular target cell types such as cancer cells in vivo or in vitro . Nucleic acid sequences encoding such proteins and methods of use relating to cancer and other therapies are provided.
摘要翻译：描述了嵌合细胞表面蛋白，其可用于在特定靶细胞类型如体内或体外的癌细胞中选择性诱导细胞凋亡。提供了编码这些蛋白质的核酸序列以及涉及癌症和其他疗法的使用方法。

4. 发明申请

WO0112579A3 NEW STILBENES WITH VASCULAR DAMAGING ACTIVITY 审中-公开
标题翻译：具有血管损伤活性的新型血栓
公开(公告)号：WO0112579A3
公开(公告)日：2001-10-11
申请号：PCT/GB0003067
申请日：2000-08-09
申请人： ANGIOGENE PHARM LTD , DAVIS PETER DAVID
发明人： DAVIS PETER DAVID
IPC分类号： A61K31/661 , A61K31/09 , A61K47/48 , A61P35/00 , C07C43/23 , C07F9/09 , C07F9/12
CPC分类号： C07C43/23 , A61K47/52 , C07F9/12
摘要： A group of novel cis-stilbenes as disclosed of formula (1) wherein: R , R and R are each independently alkyl, R is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo, R is hydrogen, alkoxy, alkyl, alkylthio, hydroxy or halo, or a pharmaceutically acceptable salt thereof or a prodrug such as a phosphate ester. These compounds have vascular damaging activity and are therefore potentially of value in treatment of diseases where reversal of neovascularisation may have therapeutic benefit.
摘要翻译：如式（1）所公开的一组新颖的顺式 - 均二苯乙烯，其中：R 1，R 2和R 3各自独立地为烷基，R 4为烷基，卤代烷基，烯基，炔基，烷硫基，烷基亚磺酰基，烷基磺酰基或卤素，R 5是氢，烷氧基，烷基，烷硫基，羟基或卤素，或其药学上可接受的盐或前体药物如磷酸酯。这些化合物具有血管损伤活性，因此可能在治疗新血管形成逆转可能具有治疗益处的疾病中具有价值。

5. 发明申请

WO0041669A3 BENZIMIDAZOLE VASCULAR DAMAGING AGENTS 审中-公开
标题翻译：苯并咪唑血管损伤剂
公开(公告)号：WO0041669A3
公开(公告)日：2000-11-16
申请号：PCT/GB0000099
申请日：2000-01-14
申请人： ANGIOGENE PHARM LTD , DAVIS PETER DAVID
发明人： DAVIS PETER DAVID
IPC分类号： A61K31/4184 , A61K31/675 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D235/32 , C07F9/6506
CPC分类号： C07F9/65068 , A61K31/4184 , A61K31/675 , C07D235/32
摘要： 5(6)-substituted benzimidazole-2-carbamates of formula (I) wherein Alk is an alkyl group, X is oxygen, sulphur, sulphinyl, sulphonyl, carbonyl (CO), thiocarbonyl (CS), sulphonyloxy, NH, iminomethylene (C=NH), N-hydroxyiminomethylene, N-alkoxyiminomethylene, dialkoxymethylene, 1,3-dioxolan-2yl, 1,1-ethenyl, a group CHR or a bond, R is hydrogen, alkylaminocarbonyl or alkoxycarbonyl, R is hydrogen, alkoxycarbonyl, cyanomethyl, cyanoethyl, alkoxymethyl or acetoxymethyl. R is hydrogen, hydroxy, alkoxy or amino, A is an optionally substituted aromatic, optionally substituted heteroaromatic, optionally substituted heterocycloalkyl, optionally substituted alkyl or optionally substituted cycloalkyl group and the pharmaceutically acceptable salt, solvates and hydrates thereof, can be used in the preparation of medicaments for the treatment of diseases involving neovascularisation.
摘要翻译：其中Alk是烷基，X是氧，硫，亚磺酰基，磺酰基，羰基（CO），硫代羰基（CS），磺酰氧基，NH，亚氨基亚甲基（C）的5（6） - 取代的苯并咪唑-2-氨基甲酸酯 = NH），N-羟基亚氨基亚甲基，N-烷氧基亚氨基亚甲基，二烷氧基亚甲基，1,3-二氧戊环-2-基，1,1-乙烯基，基团CHR 3或键，R 1是氢，烷基氨基羰基或烷氧基羰基，R 2是氢，烷氧基羰基，氰基甲基，氰基乙基，烷氧基甲基或乙酰氧基甲基。 R 3是氢，羟基，烷氧基或氨基，A是任选取代的芳族，任选取代的杂芳族，任选取代的杂环烷基，任选取代的烷基或任选取代的环烷基及其药学上可接受的盐，溶剂化物和水合物在制备用于治疗涉及新血管形成的疾病的药物中。

6. 发明公开

EP2863924A4 METHOD AND COMPOSITION FOR ALLEVIATING TUMOR SYMPTOMS 审中-公开
标题翻译：用于治疗肿瘤症状的方法和组合物
公开(公告)号：EP2863924A4
公开(公告)日：2015-12-30
申请号：EP13806597
申请日：2013-06-21
申请人： ANGIOGENE PHARM LTD , OXIGENE INC
发明人： DAVIS PETER DAVID , CHAPLIN DAVID J
IPC分类号： A61K31/661 , A61K38/12 , A61P35/00
CPC分类号： A61K31/661 , A61K38/12 , A61K38/31 , A61K45/06 , A61K2300/00

7. 发明专利

BR112014030777A2 método e composição para aliviar sintomas de tumor 未知
公开(公告)号：BR112014030777A2
公开(公告)日：2017-06-27
申请号：BR112014030777
申请日：2013-06-21
申请人： ANGIOGENE PHARM LTD , OXIGENE INC
发明人： DAVID J CHAPLIN , PETER DAVID DAVIS
IPC分类号： A61K31/66 , A61P35/00
摘要： resumo patente de invenção: “método e composição para aliviar sintomas de tumor”. esta invenção refere-se a métodos e a composições para tratamento de síndrome de carcinoide e outros sintomas adversos associados a tumores neuroendócrinos de produção de tumor, referidos métodos compreendendo administrar uma quantidade terapeuticamente eficaz de um agente de ruptura vascular, ou de um sal farmaceuticamente aceitável deste, a um indivíduo tendo um tumor neuroendócrino de produção de hormônio. em implementações preferidas, o agente de ruptura vascular é combretastatina a-4 fosfato, combretastatina a-1 difosfato ou um sal farmaceuticamente aceitável destes.

8. 发明专利

CA2362281C COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS 未知
公开(公告)号：CA2362281C
公开(公告)日：2008-11-18
申请号：CA2362281
申请日：2000-02-15
申请人： ANGIOGENE PHARM LTD
发明人： DAVIS PETER DAVID
IPC分类号： A61K45/06 , A61K31/155 , A61K31/165 , A61K31/17 , A61K31/195 , A61K31/198 , A61K31/223 , A61K31/35 , A61K31/352 , A61K31/44 , A61K31/66 , A61K31/661 , A61P3/10 , A61P9/10 , A61P17/06 , A61P19/02 , A61P27/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P37/00
摘要： Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of said compounds and treatment employing said materials.

9. 发明专利

IL144847A COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING ANGIOGENESIS 未知
公开(公告)号：IL144847A
公开(公告)日：2006-10-31
申请号：IL14484701
申请日：2001-08-09
申请人： ANGIOGENE PHARM LTD
IPC分类号： A61K31/155 , A61K31/165 , A61K31/17 , A61K31/195 , A61K31/198 , A61K31/223 , A61K31/35 , A61K31/44 , A61K31/66 , A61K45/06 , A61P3/10 , A61P9/10 , A61P17/06 , A61P19/02 , A61P27/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P37/00
摘要： Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of said compounds and treatment employing said materials.

10. 发明专利

AT339209T 未知
公开(公告)号：AT339209T
公开(公告)日：2006-10-15
申请号：AT03758296
申请日：2003-10-06
申请人： ANGIOGENE PHARM LTD
发明人： BARGE ALAN
IPC分类号： A61K31/661 , A61K31/7068 , A61P35/00
摘要： The present invention relates to a method for the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6126 in combination with gemcitabine; to a pharmaceutical composition comprising ZD6126 and gemcitabine; to a combination product comprising ZD6126 and gemcitabine for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6126 and gemcitabine; and to the use of ZD6126 and gemcitabine in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式